Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Ligand Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 38.94M 23.54M 30.04M 31.39M 48.97M
Cost of Goods Sold (COGS) incl. D&A - 2.21M 4.91M 3.6M 5.73M
COGS excluding D&A - 0 2.12M 874,000 3.07M
Depreciation & Amortization Expense 3.13M 2.21M 2.79M 2.73M 2.66M
Depreciation 3.13M 2.21M 500,000 300,000 300,000
Amortization of Intangibles - - 2.29M 2.43M 2.36M
Gross Income - 21.33M 25.13M 27.79M 43.24M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 51.95M 32.68M 25.27M 26.9M 27.26M
Research & Development 39.87M 22.07M 10.29M 10.79M 9.27M
Other SG&A 12.08M 10.62M 14.98M 16.11M 17.98M
Other Operating Expense 0 0 0 0 0
Unusual Expense 15.68M 10.51M 3.27M 1.97M 4.64M
EBIT after Unusual Expense (15.68M) (10.51M) (3.27M) (1.97M) (4.64M)
Non Operating Income/Expense 21.63M 6.08M 2.33M 516,000 (63,000)
Non-Operating Interest Income 586,000 440,000 31,000 0 0
Equity in Affiliates (Pretax) - 0 0 0 0
Interest Expense 270,000 58,000 2.51M 3.31M 2.08M
Gross Interest Expense 270,000 58,000 2.51M 3.31M 2.08M
Interest Capitalized 0 - 0 0 0
Pretax Income (9.87M) (15.4M) (3.56M) (3.87M) 9.21M
Income Tax (1.54M) (2.62M) (13.27M) (1.19M) 374,000
Income Tax - Current Domestic 23.53M (27.69M) 659,000 19,000 33,000
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic (25.07M) 25.07M (13.93M) (1.21M) 341,000
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income (8.34M) (12.79M) 9.71M (2.67M) 8.83M
Minority Interest Expense 0 0 0 0 0
Net Income (8.34M) (12.79M) 9.71M (2.67M) 8.83M
Extraordinaries & Discontinued Operations 6.39M 2.41M 3,000 2.15M 2.59M
Extra Items & Gain/Loss Sale Of Assets 6.39M 2.41M 3,000 2.15M 2.59M
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations - - 0 0 0
Net Income After Extraordinaries (1.95M) (10.37M) 9.72M (527,000) 11.42M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (8.34M) (12.79M) 9.71M (2.67M) 8.83M
EPS (Basic) - - 0.49 (0.13) 0.43
Basic Shares Outstanding - - 19.66M 19.85M 20.31M
EPS (Diluted) - - 0.49 (0.13) 0.43
Diluted Shares Outstanding - - 19.71M 19.85M 20.75M
EBITDA (13.01M) (9.15M) 2.65M 3.62M 18.65M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.